Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arvinas, Inc. (ARVN : NSDQ)

• Company Description    Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States. Number of Employees: 430

• Price / Volume Information    Yesterday's Closing Price: $7.89 Daily Weekly Monthly 20 Day Moving Average: 1,683,686 shares Shares Outstanding: 72.99 (millions) Market Capitalization: $575.90 (millions) Beta: 2.17 52 Week High: $34.11 52 Week Low: $5.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 4.23% 0.32% 12 Week -8.26% -22.83% Year To Date -58.84% -61.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5 SCIENCE PARK 395 WINCHESTER AVE - NEW HAVEN,CT 06511 USA ph: 203-535-1456 fax: - ir@arvinas.com http://www.arvinas.com

• General Corporate Information    Officers John Houston - President; Chief Executive Officer and Chairman Andrew Saik - Chief Financial Officer and Treasurer David K. Loomis - Vice President and Chief Accounting Officer Sunil Agarwal - Director Linda Bain - Director Peer Information Arvinas, Inc. (CORR.) Arvinas, Inc. (RSPI) Arvinas, Inc. (CGXP) Arvinas, Inc. (BGEN) Arvinas, Inc. (GTBP) Arvinas, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04335A105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 07/29/25 Share - Related Items Shares Outstanding: 72.99 Most Recent Split Date: (:1) Beta: 2.17 Market Capitalization: $575.90 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.75 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.51 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 1.27% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 07/29/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.87 Price/Cash Flow: - Price / Sales: 1.35 EPS Growth vs. Year Ago Period: 217.53% vs. Previous Quarter: 280.95% Sales Growth vs. Year Ago Period: 646.25% vs. Previous Quarter: 218.92% ROE 06/30/25 - - 03/31/25 - -7.74 12/31/24 - -33.75 ROA 06/30/25 - - 03/31/25 - -4.11 12/31/24 - -16.75 Current Ratio 06/30/25 - - 03/31/25 - 4.58 12/31/24 - 4.64 Quick Ratio 06/30/25 - - 03/31/25 - 4.58 12/31/24 - 4.64 Operating Margin 06/30/25 - - 03/31/25 - -10.92 12/31/24 - -75.51 Net Margin 06/30/25 - - 03/31/25 - -10.92 12/31/24 - -75.51 Pre-Tax Margin 06/30/25 - - 03/31/25 - -10.75 12/31/24 - -75.29 Book Value 06/30/25 - - 03/31/25 - 9.04 12/31/24 - 8.17 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.08 12/31/24 - 0.11

Powered by Zacks Investment Research ©